In the kinase inhibitor class of breast cancer drugs, Pfizer’s Ibrance has held a strong lead in market share—and sales—over Eli Lilly’s Verzenio.
But on the heels of Verzenio's strong showing in HR+/HER2- early breast cancer—and Ibrance's miss—one influential analyst figures the Lilly drug will quickly pick up steam. The upshot? About $4.6 billion in sales at peak, significantly more than most pharma watchers now expect from the med.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,